AstraZeneca (AZN)
(Delayed Data from NSDQ)
$81.16 USD
+0.27 (0.33%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.16 USD
+0.27 (0.33%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AstraZeneca (AZN) drug Faslodex receives FDA approval for a label extension for Faslodex in the first-line monotherapy setting for the treatment of advanced breast cancer.
Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug
by Arpita Dutt
It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.
Pfizer's Ibrance in First-Line Combo Breast Cancer Study
by Zacks Equity Research
Pfizer, Inc. (PFE) and six international cancer research groups are collaborating on a combination study to explore the use of Ibrance for first-line treatment of advanced breast cancer.
Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval
by Zacks Equity Research
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
Ironwood Pharma's Combination Gout Drug Gets FDA Approval
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.
AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion
by Zacks Equity Research
AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo
by Arpita Dutt
Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
by Zacks Equity Research
Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.
Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.
Will Nektar's (NKTR) Candidates Enhance Growth in 2017?
by Zacks Equity Research
Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Impax Laboratories (IPXL) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Impax Laboratories (IPXL) reported positive second-quarter results with earnings and sales both beating estimates. The company has strengthened its generic portfolio with additional approvals during the quarter.
Valeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View
by Zacks Equity Research
Valeant's (VRX) second-quarter results were encouraging but the company trimmed its guidance due to recent divestitures.
Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.
Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.
Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals
by Arpita Dutt
Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.
The Zacks Analyst Blog Highlights: Merck, Citigroup, AstraZeneca, HSBC and Sprint
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Citigroup, AstraZeneca, HSBC and Sprint
Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More
by Arpita Dutt
Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.
AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study
by Zacks Equity Research
AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.
Merck (MRK) Beats on Q2 Earnings and Sales, Keeps 2017 View
by Zacks Equity Research
Merck & Co., Inc. (MRK) beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda.
Ironwood (IRWD) Reports Positive Data on Reflux Candidate
by Zacks Equity Research
Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.
Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
by Arpita Dutt
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
by Zacks Equity Research
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Arena Announces Secondary Stock Worth $150M (revised)
by Zacks Equity Research
Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.
Pfizer Xeljanz Label Expansion Application Accepted by FDA
by Zacks Equity Research
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.
J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.